CD80 and Miyoshi myopathy: Conversely, in vivo blockade of the CD28-CD80/CD86 interaction with CTLA4-Ig (which is FDA approved for the treatment of rheumatoid arthritis) significantly enhanced the sensitivity to chemotherapy in a murine model of MM (84).